• Aurobindo Pharma has exclusive rights to develop and commercialize UB-612 in India and to UNICEF and non-exclusive rights in other select emerging markets

• Expected to support up to 480 million doses of UB-612 for India and other countries

• Agreement leverages Aurobindo Pharma�s existing development, commercial and manufacturing infrastructure

• Important step in ensuring equitable access and global vaccine supply during a worldwide pandemic to support COVAXX�s mission of democratizing health

HAUPPAUGE, N.Y.--(BUSINESS WIRE)--#Covid19--COVAXX, a U.S. company developing UB-612 a multitope peptide-based vaccine to fight COVID-19, today announced an exclusive agreement with Aurobindo Pharma to expand its global development and commercialization of UB-612 to India and the United Nations Children's Fund (UNICEF) agency.

�COVAXX is committed to providing an equitable distribution of UB-612 vaccine by prioritizing markets where the unmet need is greatest,� said Mei Mei Hu, co-founder and CEO of COVAXX. �During this global health crisis response, we must establish partners with the strongest capabilities, like Aurobindo, to expand the manufacturing and delivery of our vaccine. As one of the leading industry players with a strong track record of execution and investment in vaccines, Aurobindo Pharma is the ideal partner to advance UB-612 in India and other emerging nations and to support our mission of democratizing health worldwide.�

�All countries need vaccines but not all countries possess the robust, complex and costly infrastructure necessary to handle the extreme cold-chain systems required by some of the approved vaccines,� said Lou Reese, co-founder and Executive Chairman of COVAXX. �Partnering with top-tier organizations such as Aurobindo is a crucial step in expanding our global scale, reach and impact.�

Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX�s vaccine candidate, UB-612. Under the signed license agreement, Aurobindo Pharma has obtained the exclusive rights to commercialize in India and to UNICEF and non-exclusive rights in other select emerging and developing markets. COVAXX will supply the bulk product and Aurobindo will manufacture the finished doses at its facilities in Hyderabad, India. Aurobindo has an initial capacity of 220 million doses in multi-dose presentation and is building additional facilities to increase its capacity to have nearly 480 million doses manufactured by June 2021. The financial terms of the agreement are not disclosed.

Commenting on the development, Mr. N. Govindarajan, Managing Director, Aurobindo Pharma Limited, said �We are proud to join hands with COVAXX for developing the first-ever peptide-based vaccine to combat the COVID-19 pandemic. This vaccine has immense potential in eliminating shedding and hence containing the spread of the pandemic.�

This agreement is in addition to the recently announced advanced purchase commitments of more than 140 million doses of COVAXX�s UB-612 vaccine, totaling over $2.8 billion, to deliver the vaccine in multiple countries. COVAXX is currently completing a Phase 1 clinical trial of UB-612 in Taiwan and will begin Phase 2/3 clinical trials in Asia, Latin America and the U.S.

UB-612 Fact Sheet: www.covaxx.com/vaccine

About COVAXX. The mission of COVAXX is to democratize health and safeguard lives worldwide by tackling the global COVID-19 pandemic using cost-effective, scalable and proven science-based solutions. Produced from a commercially proven, vaccine platform, UB-612 is a multitope vaccine designed to activate both B and T-cell arms of the immune system. Preclinical studies have shown that the UB-612 vaccine candidate generated high titers of neutralizing antibodies.

COVAXX is a subsidiary of United Biomedical Inc (UBI), founded in 1985, with headquarters in New York. The company is a scientific trailblazer creating technological firsts, including the manufacture and commercialization of more than 100 million antibody blood diagnostic tests and 5 billion vaccine doses against infectious diseases in animal health. With proprietary access to UBI's core technology platforms, COVAXX can develop and commercialize high precision antibody tests and a promising COVID-19 vaccine that together would form a unique Differentiating Infected from Vaccinated Individuals (DIVI) system.

While COVAXX and its partners support the global effort by CEPI and the WHO to develop, manufacture and distribute COVID-19 vaccines through a program referred to as the �Covax Facility�, we are not directly related.

For more information, visit www.covaxx.com and follow us on social media. Twitter: @covaxxvaccine; Facebook: @COVAXX; LinkedIn: /COVAXX; and Instagram: @covaxxvaccine.

About Aurobindo Pharma

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company�s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company�s robust product portfolio is spread over major therapeutic areas encompassing CVS, CNS, Antibiotics, Anti-Retrovirals, Gastroenterology, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D, manufacturing and distribution set-up. The Company is marketing these products globally, in over 150 countries. Aurobindo Pharma has several WHO prequalified products. The company has completed manufacturing for conducting Phase 3 of its Pneumococcal conjugate vaccine (PCV) vaccine and expects to start Phase 3 trials for the PCV vaccine in early 2021.

For more information, www.aurobindo.com.

Contacts

Diane Murphy, COVAXX PR

+1 (310) 658.8756; [email protected]

David Schull, Russo Partners

+1 (212) 845.4271; [email protected]